Acucela Inc.

99 articles about Acucela Inc.

• Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma A/S to Screen Novel VAP-1 Inhibitor Compounds for Inflammatory Skin Diseases

  4/16/2020

  Kubota Vision Inc., formerly known as Acucela Inc., a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the signing of an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 inhibitor compounds discovered by Kubota Vision.

• Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt Disease

  2/13/2020

  Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the company has achieved over 65% subject enrollment in its ongoing phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to Stargardt disease.

• Acucela Meets with NASA and TRISH for Phase 1 Update for SS-OCT Project

  2/3/2020

  Acucela Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced that the company was invited to meet with NASA and the Translational Research Institute for Space Health *1 to present on January 30, 2020 the status of its Swept Source-OCT*2 device being developed for NASA’s Deep Space missions.

• Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatment

  1/6/2020

  Authors of the paper explored the cellular and metabolic stressors associated with degenerative retinal diseases and the potential role of visual cycle modulation with emixustat in the treatment of these diseases.

• Acucela Receives Orphan Designation From the EMA for Emixustat for the Treatment of Stargardt Disease

  6/10/2019

  Acucela Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced that the European Medicines Agency granted orphan designation to Acucela’s leading drug candidate emixustat hydrochloride for the treatment of Stargardt disease.

• Acucela Appoints Robert “Bob” J. Stevens to its Board of Directors

  5/15/2019

  Acucela Inc. announced that it has appointed Robert “Bob” J. Stevens to its Board of Directors.

• Acucela Signs Agreement to Develop a Compact OCT for NASA’s Deep Space Missions

  3/17/2019

  Acucela Inc. announced that the company signed the agreement with the Translational Research Institute for Space Health to develop a compact OCT*1 device for NASA’s Deep Space missions.

• Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Disease

  11/11/2018

  Acucela Inc. announced today that on November 7, 2018, the first patient has enrolled (FPFV; first patient first visit) in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (“emixustat”), in subjects with macular atrophy secondary to Stargardt disease.

• New Acucela Data on the Effect of Emixustat Hydrochloride on Retinal Thickness in Diabetic Retinopathy

  6/21/2018

  Acucela Inc., announced today new data on the effect of emixustat hydrochloride on retinal thickness in diabetic retinopathy (DR).

• Dr. Lukas Scheibler, Acucela’s EVP Of R&D, Presents Optogenetics At Cell & Gene Meeting On The Mesa

  10/6/2017

• Company Profile For Acucela

  10/6/2017

• Company Profile for Acucela

  10/5/2017

• Acucela Granted New Patent Covering Method Of Use For Emixustat Hydrochloride

  9/11/2017

• Acucela Initiates Phase 2a Study Of Emixustat Hydrochloride Addressing Patients With Stargardt Disease

  1/27/2017

• Acucela Receives Orphan Drug Designation From The FDA For The Treatment Of Stargardt Disease

  1/6/2017

• Acucela Secures Option To Exclusively Acquire Novel Retinal Technology

  12/14/2016

• Acucela Announces Official Name Of Acucela Japan As Kubota Pharmaceutical Holdings Co., Ltd.

  8/10/2016

• Announcement Regarding the News Coverage Concerning An Inquiry On Trades Of Acucela Shares

  6/22/2016

• Amid Insider Trader Investigations, Acucela and Otsuka Pharma Kill Glaucoma Drug Deal After Failed Trial

  6/14/2016

• Acucela Announces Top-Line Results From Phase 2b/3 Clinical Trial Of Emixustat

  5/26/2016